Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Haemonetics Analyst Ratings and Price Targets | NYSE:HAE | Benzinga
Haemonetics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Haemonetics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
JMP Securities
Raymond James
Needham
Barrington Research
1calculated from analyst ratings
Analyst Ratings for Haemonetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2025 | Buy Now | — | Baird | David Rescott58% | → $87 | Initiates | → Outperform | Get Alert |
| 05/20/2025 | Buy Now | — | JMP Securities | David Turkaly50% | $100 → $100 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/09/2025 | Buy Now | — | Raymond James | Andrew Cooper54% | $115 → $105 | Reiterates | Strong Buy → Strong Buy | Get Alert |
| 05/08/2025 | Buy Now | — | Needham | Mike Matson56% | $104 → $84 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | — | Needham | Mike Matson56% | $108 → $104 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | Raymond James | Andrew Cooper54% | $120 → $115 | Reiterates | Strong Buy → Strong Buy | Get Alert |
| 02/07/2025 | Buy Now | — | JMP Securities | David Turkaly50% | $125 → $100 | Maintains | Market Outperform | Get Alert |
| 02/07/2025 | Buy Now | — | Needham | Mike Matson56% | $112 → $108 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | Barrington Research | Michael Petusky49% | $108 → $95 | Maintains | Outperform | Get Alert |
| 12/06/2024 | Buy Now | — | JP Morgan | Rohin Patel8% | → $116 | Initiates | → Overweight | Get Alert |
| 12/04/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 12/03/2024 | Buy Now | — | Needham | Mike Matson56% | $112 → $112 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | — | Needham | Mike Matson56% | $112 → $112 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | — | Raymond James | Andrew Cooper54% | $120 → $120 | Upgrade | Outperform → Strong Buy | Get Alert |
| 09/23/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | — | CL King | Kristen Stewart49% | → $116 | Initiates | → Buy | Get Alert |
| 09/11/2024 | Buy Now | — | B of A Securities | Craig Bijou77% | → $85 | Initiates | → Neutral | Get Alert |
| 09/10/2024 | Buy Now | — | BTIG | Marie Thibault63% | → $112 | Initiates | → Buy | Get Alert |
| 08/22/2024 | Buy Now | — | Citigroup | Joanne Wuensch74% | $94 → $85 | Maintains | Neutral | Get Alert |
| 08/13/2024 | Buy Now | — | JMP Securities | David Turkaly50% | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/09/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $107 → $108 | Maintains | Outperform | Get Alert |
| 06/12/2024 | Buy Now | — | Needham | Mike Matson56% | → $112 | Upgrade | Hold → Buy | Get Alert |
| 05/10/2024 | Buy Now | — | JMP Securities | David Turkaly50% | $115 → $125 | Maintains | Market Outperform | Get Alert |
| 05/10/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $105 → $107 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Mike Matson56% | — | Reiterates | → Hold | Get Alert |
| 04/12/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | $105 → $105 | Maintains | Outperform | Get Alert |
| 02/13/2024 | Buy Now | — | Barrington Research | Michael Petusky49% | → $105 | Reiterates | Outperform → Outperform | Get Alert |
| 11/03/2023 | Buy Now | — | Barrington Research | Michael Petusky49% | $114 → $105 | Maintains | Outperform | Get Alert |
| 10/02/2023 | Buy Now | — | Citigroup | Joanne Wuensch74% | $90 → $94 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | — | Barrington Research | Michael Petusky49% | $111 → $114 | Maintains | Outperform | Get Alert |
| 05/12/2023 | Buy Now | — | Barrington Research | Michael Petusky49% | $103 → $111 | Maintains | Outperform | Get Alert |
| 05/12/2023 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $88 → $96 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | Buy Now | — | JMP Securities | David Turkaly50% | $105 → $115 | Maintains | Market Outperform | Get Alert |
| 02/08/2023 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $84 → $88 | Maintains | Equal-Weight | Get Alert |
| 02/08/2023 | Buy Now | — | Citigroup | Joanne Wuensch74% | $92 → $95 | Maintains | Neutral | Get Alert |
| 02/08/2023 | Buy Now | — | Barrington Research | Michael Petusky49% | $94 → $103 | Maintains | Outperform | Get Alert |
| 02/08/2023 | Buy Now | — | Mizuho | Anthony Petrone63% | $110 → $115 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | — | Mizuho | Anthony Petrone63% | $100 → $110 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $90 → $84 | Maintains | Equal-Weight | Get Alert |
| 12/12/2022 | Buy Now | — | Citigroup | Joanne Wuensch74% | $88 → $92 | Maintains | Neutral | Get Alert |
| 11/08/2022 | Buy Now | — | Barrington Research | Michael Petusky49% | $88 → $94 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $85 → $90 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | Buy Now | — | Mizuho | Anthony Petrone63% | $90 → $100 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | — | JMP Securities | David Turkaly50% | $90 → $105 | Maintains | Market Outperform | Get Alert |
| 11/08/2022 | Buy Now | — | Raymond James | Andrew Cooper54% | $88 → $100 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | — | Citigroup | Joanne Wuensch74% | $80 → $88 | Maintains | Neutral | Get Alert |
| 10/13/2022 | Buy Now | — | Mizuho | Anthony Petrone63% | → $90 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $74 → $85 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | — | JMP Securities | David Turkaly50% | $80 → $90 | Maintains | Market Outperform | Get Alert |
| 08/11/2022 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 08/11/2022 | Buy Now | — | Barrington Research | Michael Petusky49% | $77 → $88 | Maintains | Outperform | Get Alert |
| 08/11/2022 | Buy Now | — | Raymond James | Andrew Cooper54% | $76 → $88 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | — | Morgan Stanley | Drew Ranieri46% | $60 → $70 | Maintains | Equal-Weight | Get Alert |
| 07/01/2022 | Buy Now | — | Raymond James | Andrew Cooper54% | $63 → $76 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Haemonetics (HAE) stock?
The latest price target for Haemonetics (NYSE:HAE) was reported by Baird on June 26, 2025. The analyst firm set a price target for $87.00 expecting HAE to rise to within 12 months (a possible 16.37% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Haemonetics (HAE)?
The latest analyst rating for Haemonetics (NYSE:HAE) was provided by Baird, and Haemonetics initiated their outperform rating.
When was the last upgrade for Haemonetics (HAE)?
The last upgrade for Haemonetics Corp happened on November 8, 2024 when Raymond James raised their price target to $120. Raymond James previously had an outperform for Haemonetics Corp.
When was the last downgrade for Haemonetics (HAE)?
There is no last downgrade for Haemonetics.
When is the next analyst rating going to be posted or updated for Haemonetics (HAE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on June 26, 2025 so you should expect the next rating to be made available sometime around June 26, 2026.
Is the Analyst Rating Haemonetics (HAE) correct?
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a initiated with a price target of $0.00 to $87.00. The current price Haemonetics (HAE) is trading at is $74.76, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
